SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy
Abstract Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| doi: |
10.1101/2021.01.15.21249810 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019743947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019743947 | ||
| 003 | DE-627 | ||
| 005 | 20230429074814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210118s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.01.15.21249810 |2 doi | |
| 035 | |a (DE-627)XBI019743947 | ||
| 035 | |a (biorXiv)10.1101/2021.01.15.21249810 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Sun, Lova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection. | ||
| 700 | 1 | |a Surya, Sanjna |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Noah G. |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Anh N. |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Owoyemi, Olutosin |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Heena |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a DeLuca, Shannon |e verfasserin |4 aut | |
| 700 | 1 | |a Good, Madeline L. |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Jasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Jeffries, Seth D. |e verfasserin |4 aut | |
| 700 | 1 | |a Kry, Yolanda R. |e verfasserin |4 aut | |
| 700 | 1 | |a Kugler, Emily M. |e verfasserin |4 aut | |
| 700 | 1 | |a Mansour, Maikel |e verfasserin |4 aut | |
| 700 | 1 | |a Ndicu, John |e verfasserin |4 aut | |
| 700 | 1 | |a Osei-Akoto, AnnaClaire |e verfasserin |4 aut | |
| 700 | 1 | |a Prior, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Pundock, Stacy L. |e verfasserin |4 aut | |
| 700 | 1 | |a Varughese, Lisa A. |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, JoEllen |e verfasserin |4 aut | |
| 700 | 1 | |a Doucette, Abigail |e verfasserin |4 aut | |
| 700 | 1 | |a Dudek, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Shefali Setia |e verfasserin |4 aut | |
| 700 | 1 | |a Gouma, Sigrid |e verfasserin |4 aut | |
| 700 | 1 | |a Weirick, Madison E. |e verfasserin |4 aut | |
| 700 | 1 | |a McAllister, Christopher M. |e verfasserin |4 aut | |
| 700 | 1 | |a Bange, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Gabriel, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ritchie, Marylyn |e verfasserin |4 aut | |
| 700 | 1 | |a Rader, Daniel J. |e verfasserin |4 aut | |
| 700 | 1 | |a Vonderheide, Robert H. |e verfasserin |4 aut | |
| 700 | 1 | |a Schuchter, Lynn M |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Anurag |e verfasserin |4 aut | |
| 700 | 1 | |a Maillard, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Mamtani, Ronac |e verfasserin |4 aut | |
| 700 | 1 | |a Hensley, Scott E. |e verfasserin |4 aut | |
| 700 | 1 | |a Gross, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Wileyto, E. Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Alexander C. |e verfasserin |4 aut | |
| 700 | 1 | |a Maxwell, Kara N. |e verfasserin |4 aut | |
| 700 | 1 | |a DeMichele, Angela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.1200/OP.21.00113 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.01.15.21249810 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 05 | ||
| 953 | |2 045F |a 570 | ||